Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression. METHODS: Participants with treatment-resistant depression currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. The primary outcome was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment. RESULTS: At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT. The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group. CONCLUSIONS: SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression. Further trials are needed to determine SNT's durability and to compare it with other treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The significant ben efit observed was evident despite an average of five prior antidepressant medication trials 249 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [249]
In the citing paper
“An accel erated high- dose iTBS protocol with magnetic resonance imaging (MRI)- guided func tional connectivity targeting (Stanford neuro modulation therapy, SNT) has been found, in a double- blind randomized controlled tri al (RCT), to be significantly superior relative to sham treatment four weeks after the end of the five- day protocol.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [249]
In the citing paper
“Notably, the SAINT/SNT paradigm, shows rapid and significant effects with remission rates up to 78.6% in randomized controlled trials [108,109,110,111].”
In the citing paper
“In migraines, especially with aura, single-pulse TMS studies report significant reductions in monthly headache days, sustained up to 12 months in difficult-to-treat cohorts [107,108,109,110,111,119,120,121,122], while results for chronic migraine remain inconclusive [117,122].”
In the citing paper
“This general approach was previously reported in a clinical trial using the Stanford Accelerated Intelligent Neuromodulation Therapy for the treatment of depression 53 and subsequently validated in a follow-up study 54 .”
From Stanford Hypnosis Integrated with Functional Connectivity-targeted Transcranial Stimulation (SHIFT): a preregistered randomized controlled trial (2024) · cites this paper as [54]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“The primary outcome was MADRS (31) score 4 weeks after treatment (week 5), normalized to baseline (week 0).”
BackgroundA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 1×
“The Young Mania Rating Scale (YMRS) (34) and the Scale for Suicide Ideation (35) were administered at all primary time points to assess for safety related to mania and suicidality, respectively.”
MethodRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 4×
“Equivalent results were found for the secondary outcomes (change in scores on the 6-item HAM-D, the 17-item HAM-D, and the QIDS-SR) as well as in models with missing data imputed using the lastobservation-carried-forward method and when raw scores were used rather than change from baseline.”
MethodInfluentialAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419 · cited 1×
“The Young Mania Rating Scale (YMRS) (34) and the Scale for Suicide Ideation (35) were administered at all primary time points to assess for safety related to mania and suicidality, respectively.”
MethodO’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
Blumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363 · cited 4×
“This is a departure from the more common single-time-point criterion for response or remission used in other iTBS clinical trials for depression (10).”
BackgroundMethodResultInfluentialOkamoto, M., Dan, H., Sakamoto, K., Takeo, K., Shimizu, K., Kohno, S., Oda, I., Isobe, S., Suzuki, T., Kohyama, K., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.08.026 · Cited by 1,320
Fox, M. D., Buckner, R. L., White, M. P., Greicius, M. D., & Pascual-Leone, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.028 · Cited by 1,270 · cited 1×
“These high overall response and remission rates provide further evidence to support that dysfunction in the left DLPFCsgACC network is the predominant neural basis of depressive symptoms (21, 22, 24, 50).”
BackgroundGeorge, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 1×
“We recruited individuals for this study who had a primary diagnosis of major depressive disorder, were currently experiencing a moderate to severe depressive episode (scores $20 on the 17-item Hamilton Depression Rating Scale [HAM-D] and the Montgomery-Åsberg Depression Rating Scale [MADRS]) (6, 28), were between 22 a…”
MethodDeng, Z.-D., Lisanby, S. H., & Peterchev, A. V. (2013) · Brain Stimulation · doi:10.1016/j.brs.2012.02.005 · Cited by 1,073
Koenigs, M., & Grafman, J. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.03.004 · Cited by 956
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression
Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M., Cherian, K., Tischler, C., Nejad, R., Pankow, H., Choi, E., Aaron, H., et al. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19070720 · Cited by 802
Self-citationGrimm, S., Beck, J., Schuepbach, D., Hell, D., Boesiger, P., Bermpohl, F., Niehaus, L., Boeker, H., & Northoff, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.033 · Cited by 686
Reliability and validity of the delis-kaplan executive function system: An update.
DELIS, D. C., KRAMER, J. H., KAPLAN, E., & HOLDNACK, J. (2004) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617704102191 · Cited by 567 · cited 1×
“Potential neurocognitive side effects were assessed with a test battery administered at baseline and immediately after treatment, which included the Hopkins Verbal Learning Test–Revised (36) and subtests from the Delis-Kaplan Executive Function System (37): the Trail Making Test and the Color-Word Interference Test.”
MethodWeigand, A., Horn, A., Caballero, R., Cooke, D., Stern, A. P., Taylor, S. F., Press, D., Pascual-Leone, A., & Fox, M. D. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.028 · Cited by 487 · cited 1×
“These high overall response and remission rates provide further evidence to support that dysfunction in the left DLPFCsgACC network is the predominant neural basis of depressive symptoms (21, 22, 24, 50).”
BackgroundLevkovitz, Y., Isserles, M., Padberg, F., Lisanby, S. H., Bystritsky, A., Xia, G., Tendler, A., Daskalakis, Z. J., Winston, J. L., Dannon, P., et al. (2015) · World Psychiatry · doi:10.1002/wps.20199 · Cited by 442 · cited 2×
“We recruited individuals for this study who had a primary diagnosis of major depressive disorder, were currently experiencing a moderate to severe depressive episode (scores $20 on the 17-item Hamilton Depression Rating Scale [HAM-D] and the Montgomery-Åsberg Depression Rating Scale [MADRS]) (6, 28), were between 22 a…”
BackgroundMethodDistinct symptom-specific treatment targets for circuit-based neuromodulation
Siddiqi, S. H., Taylor, S. F., Cooke, D., Pascual-Leone, A., George, M. S., & Fox, M. D. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19090915 · Cited by 375
Stokes, M. G., Chambers, C. D., Gould, I. C., Henderson, T. R., Janko, N. E., Allen, N. B., & Mattingley, J. B. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00067.2005 · Cited by 367
Bergfeld, I. O., Mantione, M., Hoogendoorn, M. L. C., Ruhé, H. G., Notten, P., van Laarhoven, J., Visser, I., Figee, M., de Kwaasteniet, B. P., Horst, F., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0152 · Cited by 336 · cited 1×
“First, the sample size was small, as the trial was ended at the planned interim analysis because of superiority of the active treatment with a large effect size; yet, the sample size is similar to those of other clinical trials in patients with severe treatment-resistant depression (51, 52).”
ResultLisanby, S. H., Husain, M. M., Rosenquist, P. B., Maixner, D., Gutierrez, R., Krystal, A., Gilmer, W., Marangell, L. B., Aaronson, S., Daskalakis, Z. J., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.118 · Cited by 333 · cited 2×
“Comorbid anxiety in particular has been shown to reduce rTMS efficacy (4, 53, 54), perhaps because of the need for an alternative treatment target for these patients (55) or a higher incidence of benzodiazepine use in this population (56, 57).”
BackgroundLi, C.-T., Chen, M.-H., Juan, C.-H., Huang, H.-H., Chen, L.-F., Hsieh, J.-C., Tu, P.-C., Bai, Y.-M., Tsai, S.-J., Lee, Y.-C., et al. (2014) · Brain · doi:10.1093/brain/awu109 · Cited by 328
Coil design considerations for deep transcranial magnetic stimulation
Deng, Z.-D., Lisanby, S. H., & Peterchev, A. V. (2014) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.11.038 · Cited by 308
A Multidimensional Tool to Quantify Treatment Resistance in Depression: The Maudsley Staging Method
Fekadu, A., Wooderson, S., Donaldson, C., Markopoulou, K., Masterson, B., Poon, L., & Cleare, A. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04309 · Cited by 281 · cited 2×
“The number of prior antidepressant trials (mean55, SD52) and the Maudsley Staging Method total score (mean59, SD52; moderate treatment resistance) were the same for both groups.”
MethodFales, C. L., Barch, D. M., Rundle, M. M., Mintun, M. A., Mathews, J., Snyder, A. Z., & Sheline, Y. I. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.04.027 · Cited by 266
Nettekoven, C., Volz, L. J., Kutscha, M., Pool, E.-M., Rehme, A. K., Eickhoff, S. B., Fink, G. R., & Grefkes, C. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4993-13.2014 · Cited by 264 · cited 2×
“Fourth, 1,800 pulses per iTBS session were delivered rather than the typical 600 pulses per session, as 1,800 pulses of iTBS at 90% of rMT has been shown to produce greater changes in cortical excitability (18).”
MethodA Human Depression Circuit Derived From Focal Brain Lesions
Padmanabhan, J. L., Cooke, D., Joutsa, J., Siddiqi, S. H., Ferguson, M., Darby, R. R., Soussand, L., Horn, A., Kim, N. Y., Voss, J. L., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.07.023 · Cited by 246 · cited 1×
“These high overall response and remission rates provide further evidence to support that dysfunction in the left DLPFCsgACC network is the predominant neural basis of depressive symptoms (21, 22, 24, 50).”
BackgroundCash, R. F. H., Zalesky, A., Thomson, R. H., Tian, Y., Cocchi, L., & Fitzgerald, P. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.002 · Cited by 231
Zimmerman, M., Posternak, M. A., & Chelminski, I. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.03.007 · Cited by 229 · cited 1×
“Response was defined as a reduction $50% in MADRS score, and remission was defined as MADRS score #10 (42).”
MethodHeijnen, W. T., Birkenhäger, T. K., Wierdsma, A. I., & van den Broek, W. W. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ee0f5f · Cited by 223 · cited 1×
“Open-label trials of our SNT protocol have shown a remission rate of 90%, even in treatment-resistant individuals (12, 13), which is almost double the remission rate of ECT for treatment-resistant depression ( 48%), the current gold-standard treatment (27).”
BackgroundHigh-dose spaced Theta-burst TMS as a rapid-acting antidepressant in highly refractory depression
Williams, N. R., Sudheimer, K. D., Bentzley, B. S., Pannu, J., Stimpson, K. H., Duvio, D., Cherian, K., Hawkins, J., Scherrer, K. H., Vyssoki, B., et al. (2018) · Brain · doi:10.1093/brain/awx379 · Cited by 215 · cited 3×
“choices were discussed in detail in our previous publications (12, 13).”
BackgroundMethodSelf-citationFitzgerald, P. B., Hoy, K. E., Anderson, R. J., & Daskalakis, Z. J. (2016) · Depression and Anxiety · doi:10.1002/da.22503 · Cited by 204 · cited 2×
“Additionally, 62% of our participants had recurrent depressive episodes rather than one continuous episode, which has also been shown to negatively predict outcome following rTMS treatment (46).”
BackgroundSynaptic evidence for the efficacy of spaced learning
Kramár, E. A., Babayan, A. H., Gavin, C. F., Cox, C. D., Jafari, M., Gall, C. M., Rumbaugh, G., & Lynch, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120700109 · Cited by 192
Prevalence of treatment-resistant depression in primary care: cross-sectional data
Thomas, L., Kessler, D., Campbell, J., Morrison, J., Peters, T. J., Williams, C., Lewis, G., & Wiles, N. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x675430 · Cited by 175
Razza, L. B., Moffa, A. H., Moreno, M. L., Carvalho, A. F., Padberg, F., Fregni, F., & Brunoni, A. R. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.10.016 · Cited by 172 · cited 1×
“The high level of treatment resistance in our sample may also account for the relatively low remission rate observed in our sham treatment group (13%) in comparison to remission rates typically reported for sham treatment in rTMS studies (48, 49); a previous sham-controlled iTBS study showed that individuals with mode…”
ResultTrajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study
Kaster, T. S., Downar, J., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18091096 · Cited by 168 · cited 2×
“This method was chosen rather than response or remission at a single time point to allow for different response trajectories (43).”
BackgroundMethodYesavage, J. A., Fairchild, J. K., Mi, Z., Biswas, K., Davis-Karim, A., Phibbs, C. S., Forman, S. D., Thase, M., Williams, L. M., Etkin, A., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1483 · Cited by 164 · cited 1×
“The high level of treatment resistance in our sample may also account for the relatively low remission rate observed in our sham treatment group (13%) in comparison to remission rates typically reported for sham treatment in rTMS studies (48, 49); a previous sham-controlled iTBS study showed that individuals with mode…”
ResultBrakemeier, E., Luborzewski, A., Danker‐Hopfe, H., Kathmann, N., & Bajbouj, M. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.013 · Cited by 157 · cited 1×
“Comorbid anxiety in particular has been shown to reduce rTMS efficacy (4, 53, 54), perhaps because of the need for an alternative treatment target for these patients (55) or a higher incidence of benzodiazepine use in this population (56, 57).”
BackgroundSensitivity of the six‐item Hamilton Depression Rating Scale
O'Sullivan, R. L., Fava, M., Agustin, C., Baer, L., & Rosenbaum, J. F. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09649.x · Cited by 141 · cited 5×
“Thus, changes in scores on the MADRS, 6-item HAM-D, 17-item HAM-D, and QIDS-SR were assessed with generalized linear mixed models that used Satterthwaite approximation of degrees of freedom and robust estimation of coefficients to handle violations of model assumptions.”
MethodInfluentialKetamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131 · cited 1×
“First, the sample size was small, as the trial was ended at the planned interim analysis because of superiority of the active treatment with a large effect size; yet, the sample size is similar to those of other clinical trials in patients with severe treatment-resistant depression (51, 52).”
ResultHunter, A. M., Minzenberg, M. J., Cook, I. A., Krantz, D. E., Levitt, J. G., Rotstein, N. M., Chawla, S. A., & Leuchter, A. F. (2019) · Brain and Behavior · doi:10.1002/brb3.1275 · Cited by 120 · cited 1×
“Comorbid anxiety in particular has been shown to reduce rTMS efficacy (4, 53, 54), perhaps because of the need for an alternative treatment target for these patients (55) or a higher incidence of benzodiazepine use in this population (56, 57).”
BackgroundKar, S. K. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.1.25 · Cited by 117 · cited 1×
“Greater severity of depressive symptoms (45, 46) and higher levels of treatment resistance (4, 6, 47) have both been associated with poorer responses to rTMS.”
BackgroundTse, N. Y., Goldsworthy, M. R., Ridding, M. C., Coxon, J. P., Fitzgerald, P. B., Fornito, A., & Rogasch, N. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-26791-w · Cited by 114
Philip, N. S., Barredo, J., Aiken, E., & Carpenter, L. L. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.10.007 · Cited by 110 · cited 1×
“Studies will be needed that compare the efficacy of SNT parameters with and without fcMRI-guided targeting to determine the importance of this targeting method (58).”
BackgroundStokes, M. G., Barker, A. T., Dervinis, M., Verbruggen, F., Maizey, L., Adams, R. C., & Chambers, C. D. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00510.2012 · Cited by 98
Yip, A. G., George, M. S., Tendler, A., Roth, Y., Zangen, A., & Carpenter, L. L. (2017) · Brain Stimulation · doi:10.1016/j.brs.2017.02.013 · Cited by 90
Trevizol, A. P., Downar, J., Vila-Rodriguez, F., Thorpe, K. E., Daskalakis, Z. J., & Blumberger, D. M. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100349 · Cited by 70 · cited 1×
“Comorbid anxiety in particular has been shown to reduce rTMS efficacy (4, 53, 54), perhaps because of the need for an alternative treatment target for these patients (55) or a higher incidence of benzodiazepine use in this population (56, 57).”
BackgroundTargeting location relates to treatment response in active but not sham rTMS stimulation
Rosen, A. C., Bhat, J. V., Cardenas, V. A., Ehrlich, T. J., Horwege, A. M., Mathalon, D. H., Roach, B. J., Glover, G. H., Badran, B. W., Forman, S. D., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.04.010 · Cited by 55
Deppe, M., Abdelnaim, M., Hebel, T., Kreuzer, P. M., Poeppl, T. B., Langguth, B., & Schecklmann, M. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01160-9 · Cited by 47 · cited 1×
“Comorbid anxiety in particular has been shown to reduce rTMS efficacy (4, 53, 54), perhaps because of the need for an alternative treatment target for these patients (55) or a higher incidence of benzodiazepine use in this population (56, 57).”
BackgroundSeverity of Depression Predicts Remission Rates Using Transcranial Magnetic Stimulation
Grammer, G. G., Kuhle, A. R., Clark, C. S., Dretsch, M. N., Williams, K. A., & Cole, J. T. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00114 · Cited by 44 · cited 1×
“Greater severity of depressive symptoms (45, 46) and higher levels of treatment resistance (4, 6, 47) have both been associated with poorer responses to rTMS.”
BackgroundModulation of Fronto-Striatal Functional Connectivity Using Transcranial Magnetic Stimulation
Alkhasli, I., Sakreida, K., Mottaghy, F. M., & Binkofski, F. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00190 · Cited by 43 · cited 1×
“Third, we delivered stimulation sessions at an intensity of 90% of resting motor threshold (rMT), adjusted for individual differences in cortical depth at the target, rather than the FDAapproved intensity of 120% of rMT, because iTBS sessions of 1,800 pulses delivered at 90% of rMT may be more effective in inducing ch…”
MethodCao, G., & Harris, K. M. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00297.2014 · Cited by 41
Hsu, J. H., Downar, J., Vila-Rodriguez, F., Daskalakis, Z. J., & Blumberger, D. M. (2019) · Brain Stimulation · doi:10.1016/j.brs.2019.07.011 · Cited by 31 · cited 2×
“The participants in our study had an average of five previous adequate antidepressant medication trials; conventional rTMS protocols have been found to induce remission in only 17% of individuals who have shown no response to three prior antidepressant treatments (11).”
BackgroundMethodJorge, R. E., Robinson, R. G., & O'Brien, J. T. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209990603 · Cited by 3 · cited 2×
“Finally, the SNT protocol was designed to deliver a higher overall pulse dose than standard iTBS protocols (90,000 versus 18,000 pulses), because higher pulse doses are associated with greater antidepressant efficacy (19, 20).”
MethodBlumberger, D. M., Vila‐Rodriguez, F., Daskalakis, Z. J., Giacobbe, P., Lam, R. W. M., Kennedy, S. H., & Downar, J. H. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.01.258 · Cited by 3 · cited 1×
“Our protocol, previously referred to as Stanford accelerated intelligent neuromodulation therapy (SAINT) and now entitled Stanford neuromodulation therapy (SNT), includes 1) an efficient form of rTMS, termed intermittent theta-burst stimulation (iTBS) (14); 2) treatment”
Method
Research works printed but not linked: 3
- Friedrich MJ, 2017, JAMA, 317, 1517
- Cash RFH, Biol Psychiatry
- Modak A, World J Biol Psychiatry
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMarx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“…is the Stanford Neuromodula-tion Therapy protocol, which requires a reduced duration to prior TMS methods and has demonstrated a 52.5% reduction in reported average depressive symptoms from baseline in the active treatment group compared with 11.1% of participants receiving a sham treatment 220 .”
InfluentialPsilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 269
“Consistent with this notion, psilocybin produced the largest changes in the DMN, frequently associated with neuropsychiatric disorders 34,35,87–91 , and in a region of the anterior and middle hippocampus associated with the self 29,92 and the present moment 93 .”
Caulfield, K. A., Fleischmann, H. H., Cox, C. E., Wolf, J. P., George, M. S., & McTeague, L. M. (2022) · Brain Stimulation · doi:10.1016/j.brs.2022.08.013 · Cited by 145
Blumberger, D. M., Mulsant, B. H., Thorpe, K. E., McClintock, S. M., Konstantinou, G. N., Lee, H. H., Nestor, S. M., Noda, Y., Rajji, T. K., Trevizol, A. P., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2862 · Cited by 142
Metadata
- Authors
- Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., Carreon, D., Hawkins, J., Chang, M., Keller, J., Raj, K., DeBattista, C., Jo, B., Espil, F. M., Schatzberg, A. F., Sudheimer, K. D., & Williams, N. R.
- Affiliations
- Southern Illinois University Carbondale (US)
- Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, Calif. (all authors except King and Sudheimer); U.S. Department of Veterans Affairs, Palo Alto, Calif. (Phillips, Azeez, Coetzee); Department of Psychology, Palo Alto University, Palo Alto, Calif. (Stimpson, Cherian, Felber, Brown, Choi); Centre for Neuroimaging and Cognitive Genomics, National University of Ireland, Galway (King); Department of Anatomy, School of Medicine, Southern Illinois University, Carbondale (Sudheimer).
- ORCID
- Cole, Eleanor J.
- Bentzley, Brandon S.
- Stimpson, Katy H.
- Nejad, Romina
- Khan, Naushaba
- Cherian, Kirsten
- Brown, Randi
- Choi, Elizabeth
- Bishop, James H.
- Azeez, Azeezat
- Coetzee, John
- Odenwald, Nicole
- Carreon, David
- Keller, Jennifer
- Raj, Kristin
- DeBattista, Charles
- Jo, Booil
- Espil, Flint M.
- Schatzberg, Alan F.
- Sudheimer, Keith D.
- Williams, Nolan R.
- Venue
- American Journal of Psychiatry
- Published
- 2022-02
- Volume
- 179
- Issue
- 2
- Pages
- 132-141
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3208689015
- Semantic Scholar
- e244e400ad19605c257a4623dc09a7d4fa31baed
- Cited by
- 795
- References
- 55
- Citations by year
- 2026: 172 · 2025: 185 · 2024: 203 · 2023: 166 · 2022: 66
- FWCI
- 44.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, intermittent theta burst stimulation, dorsolateral prefrontal cortex, subgenual anterior cingulate cortex, sham stimulation, depression remission
- MeSH terms
- Double-Blind Method, Gyrus Cinguli, Humans, Treatment Outcome, Prefrontal Cortex, Transcranial Magnetic Stimulation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.